Effects of a Multidisciplinary Intervention on the Presence of Neuropsychiatric Symptoms and Psychotropic Drug Use in Nursing Home Residents WithYoung-Onset Dementia:Behavior and Evolution of Young-Onset Dementia Part 2 (BEYOND-II) Study by Appelhof, Britt et al.
  
 University of Groningen
Effects of a Multidisciplinary Intervention on the Presence of Neuropsychiatric Symptoms and
Psychotropic Drug Use in Nursing Home Residents WithYoung-Onset Dementia
Appelhof, Britt; Bakker, Christian; de Vugt, Marjolein E; van Duinen-van den IJssel, Jeannette
C L; Zwijsen, Sandra A; Smalbrugge, Martin; Teerenstra, Steven; Verhey, Frans R J;
Zuidema, Sytse U; Koopmans, Raymond T C M
Published in:
American Journal of Geriatric Psychiatry
DOI:
10.1016/j.jagp.2018.12.032
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Final author's version (accepted by publisher, after peer review)
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Appelhof, B., Bakker, C., de Vugt, M. E., van Duinen-van den IJssel, J. C. L., Zwijsen, S. A., Smalbrugge,
M., ... Koopmans, R. T. C. M. (2019). Effects of a Multidisciplinary Intervention on the Presence of
Neuropsychiatric Symptoms and Psychotropic Drug Use in Nursing Home Residents WithYoung-Onset
Dementia: Behavior and Evolution of Young-Onset Dementia Part 2 (BEYOND-II) Study. American Journal
of Geriatric Psychiatry, 27(6), 581-589. https://doi.org/10.1016/j.jagp.2018.12.032
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 21-05-2020
Number of words main text: 3022 
                                                                  Keywords:  young-onset dementia, nursing home,  
      neuropsychiatric symptoms, aggression, 
                                                                                psychotropic drug use, intervention 
Effects of a multidisciplinary intervention on the presence of neuropsychiatric 
symptoms and psychotropic drug use in nursing home residents with young-onset 













Jeannette C. L. van Duinen-van den IJssel MSc
1 3





, Steven Teerenstra MSc, PhD
7
, Frans R. J. Verhey MD, PhD
5
, Sytse 
U. Zuidema MD, PhD
8




¹ Radboud university medical center, Radboud Institute for Health Sciences, Department of 
Primary and Community care, Nijmegen, The Netherlands. 
² Archipel, Landrijt, Knowledge Center for Specialized Care, Eindhoven, the Netherlands 
³ Radboudumc Alzheimer Center, Nijmegen, The Netherlands 
4 
Florence, Mariahoeve, Center for Specialized Care in Young-Onset Dementia, The Hague, 
the Netherlands  
5 
School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht 
University Medical Center, Maastricht, the Netherlands 
6 
Department of General Practice and Elderly Care Medicine/ Amsterdam Public Health 
research institute, VU University Medical Center, Amsterdam, the Netherlands  
7 
Section Biostatistics, Department of Health Evidence, Radboud Institute for Health Sciences, 
Radboud university medical center, Nijmegen, The Netherlands 
8 
Department of General Practice and Elderly Care Medicine, University of Groningen, 
University Medical Center Groningen, Groningen, the Netherlands 








Britt Appelhof MSc. 
Department of Primary and Community Care, Radboud University Medical Center, Nijmegen  
P.O. Box 9101, 6500 HB Nijmegen, The Netherlands 
Britt.Appelhof@radboudumc.nl  
Telephone number: 00316-12153976 
 
Funding sources 
This study was funded by the Netherlands Organization for Health Research and 
Development (ZonMW, nr: 733050402), the Archipel Care Group in the Netherlands, the 
Florence Care Group in the Netherlands, the Dutch YOD Knowledge Center, and the Dutch 
Alzheimer Society  




Objectives: The effect of an intervention on the presence of neuropsychiatric symptoms 
(NPS), particularly agitation and aggression,  and psychotropic drug use (PDU) in 
institutionalized people with young-onset dementia (YOD) was evaluated.  
Design: A randomized controlled trial was conducted using a stepped wedge design. Thirteen 
YOD special care units were randomly assigned to three groups, which received the 
intervention at different time points. Four assessments took place every six months during a 
period of eighteen months.  
Setting and participants: Two hundred and seventy-four people with YOD  residing on YOD 
special care units participated, of whom 131 in all assessments. 
Intervention: The intervention consisted of an educational program combined with a care 
program, which structured the multidisciplinary process of managing NPS. The care program 
included the following five steps: the evaluation of psychotropic drug prescription, detection, 
analysis, treatment and evaluation of treatment of NPS. 
Measurements: The Cohen-Mansfield Agitation Inventory and the Neuropsychiatric 
Inventory, nursing home version were used to assess NPS. Data on PDU was retrieved from 
residents’ medical files. Multilevel models were used to evaluate the effect of the 
intervention, which accounted for clustering of measurements within clients, within units. 
Results: No significant differences on agitation and aggression, other NPS, and PDU after 
crossing over to the intervention condition were found.  
Conclusions: We found no evidence that the intervention for the management of NPS in 
nursing home residents with YOD was more effective in reducing agitation and aggression, 








When dementia occurs before the age of 65, this is most commonly referred to as young-onset 
dementia (YOD). Of the nursing home (NH) residents with YOD, 90% show one or more 
neuropsychiatric symptoms (NPS) (1). These high rates are troublesome given the serious 
negative health outcomes associated with NPS in dementia, such as loss of quality of life of 
the NH resident, high workload and distress of professional care givers, and increased costs of 
care (2-7). Comorbidity is less common at least in people in with young-onset Alzheimer 
disease than in people with late-onset Alzheimer disease, suggesting that people with YOD 
are less frail (8). As a consequence, NPS in YOD might be more severe compared to late-
onset dementia (LOD) because of increased physical fitness, such as walking speed and 
strength. Indeed, a recent study by van Duinen-van den IJssel et al. (2017) showed that NH 
staff caring for people with YOD experience more distress related to NPS compared to NH 
caring for people with LOD (7). Psychotropic drug use (PDU) is common in the management 
of NPS in NH residents with LOD and YOD (9, 10). PDU is associated with poor health 
outcomes, such as stroke, increased mortality, and reduced quality of life (3, 11, 12). 
However, still between 76.9 - 87.6% of the NH residents with YOD use one or more 
psychotropic drug(s) (4, 9). Those rates seem higher compared to PDU in NH residents with 
LOD (9).  
The high prevalence rates of NPS and PDU stress the need for the development and 
evaluation of nonpharmacological interventions in YOD. To successfully manage NPS, many 
models emphasize that the underlying causes of NPS need to be identified and treated (13). 
One of these models is the unmet-needs framework, in which NPS are perceived as behaviors 
through which the person with dementia might indirectly communicate an underlying need 
(13). Needs can be medical (e.g., physical illness, pain, and mobility), psychosocial (e.g., life 
habits, and premorbid personality), or environmental (e.g. under/over stimulation, and 
    
5 
 
behavior of NH staff/ other residents) (14, 15). People with YOD have specific age-related 
care needs regarding daytime activities, social interaction, intimate relationships, and 
information, which are often unmet (16). With knowledge of the underlying causes of NPS, 
an intervention can be individualized to the specific needs of the residents, instead of 
suppressing the behavior with the use of psychotropic drugs, concealing behavior through 
which the person with dementia might indirectly communicate an underlying need (14, 17, 
18).  
In the current study, the effect of a multidisciplinary intervention for the management 
of NPS in NH residents with YOD was evaluated (19, 20). The intervention was based on the 
“Grip on challenging behavior” care program that has shown effectiveness in the management 
of NPS in LOD (19-22).  
The aims of the study are to (1) evaluate the effect of the intervention on the 
prevalence of NPS, particularly agitation and aggression, compared to care as usual, and (2) 
evaluate the effect of the intervention on PDU.  
 
Methods 
This cluster randomized controlled trial (RCT) is part of the Behavior and Evolution of 
Young-ONset Dementia, part 2 (Beyond-II) study  (23). Process data was assessed in order to 
be able to interpret the outcomes of this RCT (24). The process data showed sufficient 
internal and external validity allowing for further effect analyses (24, 25).  
 
Setting and subjects 
In this study, thirteen YOD special care units (SCUs) participated, which are care units 
delivering specialized treatment and support for people with YOD (24). The YOD-SCUs were 
recruited through NHs that are affiliated with the Dutch YOD Knowledge Center (DKC). 
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Residents with a dementia diagnosis with a symptom onset before the age of 65 who resided 
on the YOD SCU for at least one month were eligible for inclusion in the study. The 
exclusion criteria were lack of informed consent provided by the legal representative, 
dementia caused by human immunodeficiency virus (HIV), traumatic brain injury, Down’s 
syndrome, Korsakov syndrome or Huntington’s disease. Diagnoses of dementia subtype were 
made before inclusion, according to internationally accepted criteria for diagnosing dementia 
subtypes and were retrieved from medical files (26-31). Newly admitted residents were 
recruited until the end of the study, replacing deceased residents and residents who moved to 
another care unit during the study.  
 
Intervention 
The development of the intervention ‘Grip on NPS in institutionalized people with YOD’ is 
described in detail elsewhere (20). To increase implementation, the NH staff received an 
educational program that consisted of 2 training sessions (of 2.5 and 1.5 hours). In the 
educational program, causes and mechanisms of NPS were discussed with the NH staff and 
the use and relevance of the care program was explained. After receiving the educational 
program, the care program on the management of NPS was implemented (figure 1). The care 
program provided guidance for the multidisciplinary team involved in the management of 
NPS in Dutch NHs to structure the process of detection, analysis, treatment, and evaluation of 
NPS. This care program consisted of five steps, which were consecutive and formed a cycle, 
except for the evaluation of appropriateness of psychotropic drug prescription. This separate 
step was a tool for the evaluation of appropriateness of psychotropic drug prescription by the 
elderly care physician (32, 33). The tool was performed for all residents (with or without 
NPS) in the first two months after the SCU was enrolled in the intervention condition. After 
the initial screening, the tool was used at the physician’s own discretion. The other four 
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consecutive steps of the care program had a circular structure (figure 1). Detection of NPS 
occurred through usual observations of the multidisciplinary team or with the systematic use 
of a screening tool every six months by a vocational nurse. When NPS were detected, a 
structured analysis of possible causes of the NPS observed was conducted by the (vocational) 
nurse. This analysis included a tool for the detection of unmet needs possibly underling the 
NPS (34). When necessary, the elderly care physician and/or the psychologist continued the 
analysis. After this analysis, treatment options were discussed within the multidisciplinary 
team and a treatment plan was established by the elderly care physician and/or the 
psychologist. The care program did not prescribe a specific intervention. The choice of the 
intervention relied on the hypothesized causes of the NPS, the preferences of the resident, and 
the available options in the NH. However, psychosocial treatments were preferred, with PDU 
only if other treatments had little or no effect. The treatment outcomes were evaluated by the 
multidisciplinary team and if unsatisfactory, other treatments were considered or the analysis 




To evaluate the effect of the intervention, a stepped wedge design was used (Table 1). This 
design allowed the YOD SCUs to crossover from the control to the intervention condition 
over time, assuring that all YOD SCUs received the intervention (35). The thirteen YOD 
SCUs were randomly assigned to three groups. Every six months a new group entered the 
intervention condition. The control condition consisted of care as usual without the 
educational program and use of the care program. Four assessments took place every six 
months during a period of eighteen months (September 2015 - April 2017).  
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Data collection and ethical considerations 
The Beyond-II study protocol was approved by the Medical Ethics Committee region 
Arnhem/Nijmegen (file number 2015‐1558) and registered in the Dutch Trial Register (Trial 
ID NTR5018). This research project was conducted according to the principles of the 
Declaration of Helsinki (version November 2013, www.wma.net) and in agreement with the 
laws regarding medical-scientific research in humans (WMO).  
Written informed consent was obtained from the legal representative of each resident. 
After receiving informed consent, trained researchers and research assistants collected the 
data from the resident’s medical files and through structured interviews with nursing staff.  
 
Primary outcome 
The Dutch version of the Cohen-Mansfield Agitation Inventory (CMAI-D) was used to assess 
agitation and aggression (14, 36). The CMAI has a well-established validity and reliability 
and assesses 29 agitated or aggressive behaviors (36). The frequency of each symptom is 
rated on a seven-point frequency scale (range 1-7) ranging from never to several times an 
hour. We used CMAI factors based on a previous study in LOD in which three CMAI factors 
in a large NH sample were found: physically non-aggressive behaviors (range 7-49), 




To determine effects of the care program on other NPS, the Dutch version of the 
Neuropsychiatric Inventory-nursing home version (NPI-NH) was used. The NPI-NH has a 
high interrater reliability and is found to be a valid instrument for the assessment of a wide 
range of NPS in dementia (38). The NPI-NH consists of twelve neuropsychiatric symptoms: 
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delusions, hallucinations, agitation/aggression, depression, anxiety, euphoria, apathy, 
disinhibition, irritability, aberrant motor, nighttime behavior disturbances, and eating 
disturbances. For each symptom a screening question is used to determine whether the 
symptom is present. If the symptom is present, Frequency (F) and Severity (S) are rated on a 
four-point (ranging from 1-4) and three-point Likert-scale (ranging from 1-3), for each 
symptom, respectively. Scores for each symptom are calculated as F x S (ranging from 1-12). 
A symptom score of at least 4 is considered clinically relevant (39).  
PDU was derived from the nursing homes pharmacists’ electronic files and was 
classified according to the Anatomical Therapeutic Chemical (ATC) classification system into 
antipsychotics, anxiolytics, hypnotics, antidepressants, anti-epileptics, anti-dementia drugs, 
and any psychotropic medication (40). Medication as needed, which is medication that is not 
taken according to a fixed schedule but only given in the prescribed dosage if needed, was not 
included because it was unclear if and how often these drugs were actually used. Furthermore, 
anti-epileptics used by residents with epilepsy were not registered as PDU. 
 
Other measurements 
Medical and demographic data were extracted from the resident’s medical files. Data on 
dementia subtype, age, gender, length of stay at the SCU, and date of inclusion were recorded. 
Dementia severity was assessed with the Global Deterioration rating Scale (GDS) (41). The 
GDS describes seven different stages of dementia on a seven-point scale (1-7), ranging from 
“subjectively and objectively normal cognition” to “severe cognitive decline”.  
 Process data showed that the fidelity of the intervention differed between SCUs (24). 
Therefore, fidelity was conceptualized into an implementation score consisting of three 
components. A score was calculated for the step detection based on the number of times the 
step was completed with regard to the number of residents residing on the SCU (score 2 if 
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used at least once every six months for 75-100% of all residents, score 1 if used for 50-74%, 
score 0 if used in  <50%) (24). In addition, the NH staff rated the percentages of cases with 
challenging behavior in which they worked according to the care program on a questionnaire 
(score 2 if used in 75-100% of the cases, score 1 if used in 50-74%, score 0 if used in  <50%). 
At last, two authors closely involved in the implementation (J. D. and B. A.) separately rated 
the implementation based on their communication with the SCUs about the progress of the 
implementation (ranging from 0-2). Disagreements were solved by discussion. The scores on 
the three components were summed, resulting in a total implementation score (ranging from 0 
– 6).  
 
Statistical analysis 
All analyses were performed using the Statistical Package for the Social Sciences (SPSS) 
version 22. Demographic variables of the NH residents at time of enrolment in the study were 
described by means or proportions.  
Multilevel model analyses were used to adjust for the clustering of residents in the 
thirteen different SCUs (random effect for SCU) and the correlation of the repeated measures 
within the residents (random effect for resident, nested within SCU). Time and interaction of 
time with treatment were included as a fixed effect to model time trend (in absence of 
treatment) and the effect of treatment, respectively. Multilevel models were fitted with the 
restricted maximum likelihood method and the 95%-confidence intervals and p-value of the 
coefficients in the model were based on Wald-test and t-distribution with Satterthwaite 
approximation of the degrees of freedom. The twelve symptom scores on the NPI-NH were 
dichotomized into clinically relevant symptoms (symptom score ≥4) or no clinically relevant 
symptoms (symptom score <4). Data on PDU was also dichotomized (present or absent) for 
each category. In case of binary variables, the fit for logistic and linear mixed model logistic 
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regression were compared by comparing the observed and predicted profiles of SCUs over 
time. In the case of an equal or better fit, we used linear regression instead of logistic 
regression as this allows a direct interpretation in terms of change of percentage over time.  
 In a previous study evaluating the effect of the intervention in LOD, dementia severity 
and time being exposed to the intervention had an influence on the intervention effect (21). In 
addition, differences in fidelity between SCUs could influence the intervention effect (24). 
Therefore, to investigate whether the intervention effect was different for residents with more 
advanced dementia (GDS score <5 mild, score = 5 moderate, or score ≥6 severe), or for 
residents exposed to the intervention for a longer period of time (0-6 months, 6-12 months, or 
12-18 months), or for a higher fidelity (implementation score), interaction effects between the 
intervention and these variables were investigated. In all analyses, a p value <0.05 was 
considered statistically significant. 
 
Results 
In total, 274 NH residents with YOD participated in this study. Table 2 provides demographic 
and clinical characteristics of the nursing home residents at time of inclusion. Seventy-six 
residents were lost to follow-up because they moved to another care unit or deceased before 
the end of the study. Sixty-seven newly admitted residents were included after T0.  
For all variables (including binary variables), linear multilevel regression models were 
used because these models had a better or equally good fit, and in case of binary variables, 
were consistent with the logistic multilevel models in terms of the predicted percentage in 
each of the institutions at each of the time points or better. In face of this consistency, we have 
chosen for the linear mixed model as this has an easier interpretation as absolute difference in 
percentages. The analyses showed no significant effect of the intervention on physically 
aggressive behaviors (Estimate=.495, p=.303), physically non-aggressive behaviors 
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(Estimate=-.137,p=.825), and verbally agitated behaviors (Estimate=-.176, p=697) (Table 4.). 
Additionally, no effect of the intervention on other NPS and PDU was found (Table 4.). 
 
No significant interaction effects between dementia severity and fidelity and the intervention 
effect were found. A significant interaction effect for the effect of the intervention and the 
time that a resident was exposed to the intervention with regard to the prevalence of delusions 
was found (p = .024). After being exposed for a longer period of time to the intervention it 
became more effective in decreasing delusions, with an estimated intervention effect of -.06 
(p = .056) for SCUs which worked 0-6 months with the intervention to an estimated 
intervention effect of -.06+2*-.06 (estimated intervention effect = -.18, p =0.08) for SCUs 




To our knowledge, this is the first study that evaluated the effects of a multidisciplinary 
intervention on the management of NPS in NH residents with YOD on the presence of NPS, 
particularly agitation and aggression, and PDU. We found no evidence that the intervention 
was more effective in reducing agitation and aggression, other NPS, or PDU compared to care 
as usual. 
An intervention for the management of NPS and PDU in LOD, on which our 
intervention was based, was able to diminish NPS and PDU (21). An explanation for the 
differences in effects between the original intervention and the adapted intervention for YOD 
might be that all participating SCUs in our study were recruited through NHs that were 
affiliated with the DKC. Only care organizations offering specialized care for people with 
YOD are affiliated with the center. Therefore, they might have already (to some degree) 
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developed effective working methods for the management of NPS in YOD before 
implementation of our intervention. Indeed, the process evaluation revealed that the NH staff 
experienced overlap between the intervention and their current working methods (24). In 
addition, although most NH staff was satisfied with the overall content of the care program, 
some steps of the intervention (like detection and tool to monitor PDU) were often rated as 
irrelevant (24). This suggests that users of the intervention did not expect that these steps 
would be more effective in diminishing NPS and PDU compared to care as usual in YOD 
SCUs. Possibly, in YOD SCUs there was less need for an intervention, which structured the 
management of NPS compared to LOD care units. The needs from one setting (LOD care 
units) cannot be completely generalized to another setting (YOD SCUs). 
Despite adding a tool to the intervention for monitoring PDU, no significant decrease 
in PDU after implementation of the intervention was found. A possible explanation could be 
that the current policy that favors limiting the prescription of psychotropic drugs, has already 
positively influenced the prescription pattern to some degree, leaving less room for 
improvement. Indeed, when comparing the PDU rates in our study (68.6% using at least one 
drug) with the PDU rates in NH residents with YOD approximately 10 years ago (87.6% 
using at least one drug), the PDU rates in our study appear considerably lower (4).  
Our results suggest that after working longer with the intervention, it became more 
effective in decreasing delusions. However, not even a trend towards increasing or decreasing 
effectiveness was found for other NPS. Therefore, we expected that this interaction effect 
might have been a result of multiple testing. 
 An important strength of this study was that we were able to include a large sample 
size of NH residents, resulting in sufficient study power (80% for an effect of 0.4xSD) (23). 
This is an advantage, especially in research on YOD, because the prevalence of NH residents 
with YOD is much lower compared to LOD. Also, some limitations of this study should be 
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considered. The presence of NPS was based on observations of nurses who could not be 
blinded. Awareness of being in the intervention or control condition might have influenced 
their ratings to some degree. Furthermore, no assessment instruments are available which take 
into account the specific characteristics of younger individuals with dementia. Therefore, we 
chose to measure NPS with assessment instruments designed and validated for the use in NH 
residents with LOD (36, 38). However, the CMAI does not extensively assess behavior 
associated with frontal lobe dysfunction, which might be more likely to occur in younger NH 
residents with dementia because of the higher prevalence of FTD (1). At last, we decided to 
not include medication as needed in the effect analysis, because in our study we did not 
collect data on how often these drugs were actually used. Therefore, we could not establish 
the influence of the intervention on the admission of medication as needed.  
 
Conclusions  
We found no evidence that the intervention was more effective in reducing agitation and 
aggression, other NPS, or PDU compared to care as usual. The perceived overlap between the 
intervention and their current working methods and the lower PDU rates compared to 
approximately 10 years ago, suggests that YOD SCUs have already (to some degree) 
developed effective working methods for structuring the management of NPS in YOD before 
implementation of our intervention, diminishing the intervention effect. In future studies, 
more research on the specific needs and context of YOD SCUs during the development phase 
of an intervention is important to improve relevance and effectiveness of an intervention in 
this specific context. 
 
Disclosure Statement 
All authors declare no conflicts of interest. 





1. Mulders AJMJ, Zuidema SU, Verhey FR, Koopmans RTCM. Characteristics of
 institutionalized young onset dementia patients – the BEYOnD study. International
 Psychogeriatrics 2014; 12:1973–81 
2. Murman DLD. The incremental direct costs associated with behavioral symptoms in AD. 
Neurology 2002;59(11): 1721-9 
3. Wetzels R, Zuidema S, de Jonghe J, et al: Determinants of quality of life in nursing home
 residents with dementia. Dement Geriatr Cogn Disord 2010; 29(3):189-97 
4. Mulders AJMJ, Fick IWF, Bor H, et al: Prevalence and correlates of neuropsychiatric 
symptoms in nursing home patients with young-onset Dementia: The BEYOnD Study. 
JAMDA 2016; 17(6):495-500 
5. Zwijsen SA, Kabboord A, Eefsting JA, et al: Nurses in distress? An explorative study into the
 relation between distress and individual neuropsychiatric symptoms of people with dementia
 in nursing homes. International Journal of Geriatric Psychiatry 2014; 29(4):384-91 
6. Appelhof B, Bakker C, van Duinen-van den IJssel JCL, et al: The Determinants of Quality of
 Life of Nursing Home Residents with Young-Onset Dementia and the Differences between
 Dementia Subtypes. Dementia and Geriatric Cognitive Disorders 2017; 43(5-6):320-9 
7. van Duinen-van den IJssel JCM, Mulders AJMJ, Smalbrugge M, et al: Nursing Staff Distress
 Associated With Neuropsychiatric Symptoms in Young-Onset Dementia and Late-Onset
 Dementia. Journal of the American Medical Directors Association 2017; Epub ahead of print 
8. Gerritsen AJ, Bakker C, Verhey RJ, et al: Prevalence of Comorbidity in Patients With Young-
Onset Alzheimer Disease Compared With Late-Onset: A Comparative Cohort Study. JAMDA 
2016; 17(4):318-23 
9. Appelhof B., Bakker C, van Duinen-van den IJssel JCL, et al: Differences in neuropsychiatric
 symptoms between nursing home residents with young-onset dementia and late-onset
 dementia. Aging and Mental Health 2018; Epub ahead of print 
    
16 
 
10. Wetzels RB, Zuidema SU, De Jonghe JFM, Verhey FRJ, Koopmans RTCM. Prescribing
 pattern of psychotropic drugs in nursing home residents with dementia. International
 Psychogeriatrics 2011; 23(8):1249-59 
11. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nature Reviews
 Neuroscience 2006; 7(6):492-500 
12. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics
 for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of
 Geriatric Psychiatry 2006; 14(3):191-210 
13. Cohen-Mansfield JJ. Nonpharmacologic interventions for inappropriate behaviors in dementia:
 a review, summary, and critique. The American journal of geriatric psychiatry: official journal
 of the American Association for Geriatric Psychiatry 2001; 9(4):361-81 
14. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly. A conceptual review. Journal
 of the American Geriatrics Society 1986; 34:711–21 
15. Cohen-Mansfield JJ. Heterogeneity in dementia: challenges and opportunities. Alzheimer
 Disease and Associated Disorders 2000; 14(2):60-3 
16. Bakker C, de Vugt ME, van Vliet D, et al: The relationship between unmet care needs in
 young-onset dementia and the course of neuropsychiatric symptomps: a two year follow-up
 study. International Psychogeriatrics 2014; 26(12):1991–2000 
17. Kovach CR, Noonan PE, Schlidt AM, Wells T. A model of consequences of need-driven,
 dementia-compromised behavior. Journal of nursing scholarship: an official publication of
 Sigma Theta Tau International Honor Society of Nursing / Sigma Theta Tau 2005; 37(2):134
 40 
18. Edvardsson D, Winblad B, Sandman PO. Person-centred care of people with severe
 Alzheimer's disease: current status and ways forward. The Lancet Neurology 2008; 7(4):362-7 
19. Zwijsen SA, Smalbrugge M, Zuidema SU, et al: Grip on challenging behaviour: a
 multidisciplinary care programme for managing behavioural problems in nursing home
 residents with dementia. Study protocol. BMC Health Services Research 2011; 11(41):1-6. 
    
17 
 
20. Zwijsen SA, Gerritsen DL, Eefsting JA, et al: The development of the Grip on Challenging
 Behaviour dementia care programme. International journal of palliative nursing 2014;
 20(1):15-21 
21. Zwijsen SA, Smalbrugge M, Eefsting JA, et al: Coming to grips with challenging behavior: a
 cluster randomized controlled trial on the effects of a multidisciplinary care program for
 challenging behavior in dementia. Journal of the American Medical Directors Association
 2014; 15(7):531.e1-.e10 
22. Zwijsen SA, Gerritsen DL, Eefsting JA, et al: Coming to grips with challenging behaviour: a
 cluster randomised controlled trial on the effects of a new care programme for challenging
 behaviour on burnout, job satisfaction and job demands of care staff on dementia special care
 units. International journal of nursing studies 2015; 52(1):68-74 
23. van Duinen-van den IJssel JCL, Appelhof B, Zwijsen SA, et al: Behavior and Evolution of
 Young-ONset Dementia part 2 (BEYOND-II) study: an intervention study aimed at the
 improvement of the management of challenging behavior in institutionalized people with
 young-onset dementia International Psychogeriatrics 2017; Epub ahead of print 
24. Appelhof B, Bakker C, van Duinen-van den IJssel JCL, et al: Process evaluation of an
 intervention for the management of neuropsychiatric symptoms in institutionalized people
 with young-onset dementia: the Beyond-II study. Journal of the American Medical Directors
 Association 2018; 30(3):437-446 
25. Leontjevas R, Gerritsen DL, Koopmans RTCM, et al: Process Evaluation to Explore Internal
 and External Validity of the “Act in Case of Depression” Care Program in Nursing Homes.
 Journal of the American Medical Directors Association 2012; 13(5):488.e1-.e8 
26. American Psychiatric Association. Diagnostic and Statistical manual of mental Disorders-
 Text revision: DSM-IV-TR. Washington, DC: American Psychiatric Association, 2000. 
27. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive
 aphasia and its variants. Neurology 2011; 76(11):1006-14 
    
18 
 
28. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with
 Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Journal of
 Alzheimer's Disease 2006; 9:417-23 
29. McKhann GD, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease:
 report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and
 Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-44 
30. Rascovsky K, Hodges JR, Knopman D, et al: Sensitivity of revised diagnostic criteria for the
 behavioural variant of frontotemporal dementia. Brain: a journal of neurology 2011; 134(Pt
 9):2456-77 
31. Roman GC, Tatemichi TK, Erkinjuntti T, et al: Vascular dementia: diagnostic criteria for
 research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;
 43(2):250-60 
32. van der Spek K, Gerritsen DL, Smalbrugge M, et al: A reliable and valid index was developed
 to measure appropriate psychotropic drug use in dementia. Journal of clinical epidemiology.
 2015; 68(8):903-12 
33. van der Spek K, Gerritsen DL, Smalbrugge, et al: PROPER I: frequency and appropriateness
 of psychotropic drugs use in nursing home patients and its associations: a study protocol.
 BMC Psychiatry 2013; 13:1-7 
34. Orrell M, Hancock G. CANE: Camberwell Assessment of Need for the Elderly. London:
 Gaskell, 2004 
35. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC medical
 research methodology 2006; 6:54 
36. de Jonghe JF, Kat MG. Factor structure and validity of the Dutch version of the Cohen
 Mansfield Agitation Inventory (CMAI-D). Journal of the American Geriatrics Society 1996;
 44:888-9 
37. Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT. Agitation in Dutch institutionalized
 patients with dementia: factor analysis of the Dutch version of the Cohen-Mansfield Agitation
 Inventory. Dementia and Geriatric Cognitive Disorders 2007; 23(1):35-41 
    
19 
 
38. Wood S, Cummings JL, Hsu MA, et al: The Use of the Neuropsychiatric Inventory in Nursing 
Home Residents. The American Journal of Geriatric Psychiatry 2000; 8:75-83.  
39. Zuidema SU, Derksen E, Verhey FR, Koopmans RT. Prevalence of neuropsychiatric
 symptoms in a large sample of Dutch nursing home patients with dementia. International
 Journal of Geriatric Psychiatry 2007; 22(7):632-8 
40. WHO. Anatomical Therapeutical Chemical (ATC) classification index including defined daily
 doses (DDDs) for plain substances. Oslo: World Health Organisation Collaborating Centre for
 Drug Statistics Methodology, 1997 
41. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment
 of primary degenerative dementia. The American Journal of Psychiatry 1982;139:1136–9. 
  
    
20 
 




The elderly care 
physician evaluates all 
PD’s prescribed for NPS
Detection
Every six months the 
nursing staff screens all 
patients of the special 
care unit on symptoms 
on NPS
Symptoms of NPS can 





1. symptoms of NPS 
expression of presently 
existing NPS?
2. Description of NPS and 
unmet needs by the 
nursing staff.
3. Systematic analysis of 
contibuting factors 
coordinated by psychogist 





at the contributing 

















No NPSNo symptoms of NPS No NPS
  
Figure 1. The five steps of the care program ‘Grip on NPS in institutionalized people 
with YOD (23).  
Reprinted with permission 
NPS = Neuropsychiatric Symptoms, PD’s = Psychotropic Drugs.   
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Table 1. Stepped wedge design  
 
 Group 1 Group 2 Group 3‡ 
T0 0 * 0 0 
T1 1 † 0 0 
T2 1 1 0 
T3 1 1 1 
Reprinted with permission (23) 
* 0 = control condition 
 †1= intervention condition. 
There are four, half yearly assessments. Each group consists of four or five YOD-SCU’S  
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Table 2. Demographic and clinical characteristics of the nursing home residents at time 
of inclusion (n = 274) 
 




Gender Male n (%) 138 (50.4) 








n (%)  
     Mild (2,3,4)  43 (15.7) 
     Moderate (5)  57 (20.8) 
     Severe (6,7)  172 (62.8) 
Dementia subtype n (%)  
     Alzheimer’ disease  120 (43.8) 
     Vascular dementia  29 (10.6) 
     Frontotemporal dementia  80 (29.2) 
    Mixed Alzheimer/vascular  14 (5.1) 
    Lewy Body/ Parkinson  5 (1.8) 
    Alcohol related dementia  6 (2.2) 
     Other  20 (7.3) 
* SD = Standard Deviation  
† SCU = Special Care Unit 
‡ = 1 missing 
§  GDS = Global Deterioration Scale 
||= 5 missing  
    
23 
 
Table 3. Baseline data on outcome variables at the time of inclusion (n=227)* 
 
CMAI† factor scores Mean (SD‡)  
   Physically aggressive behaviors  13.02 (6.41) 
   Physically nonaggressive behaviors  14.86 (7.90) 
Verbally agitated behaviors  8.46 (5.90) 
Clinical relevant NPI-NH§ n (%) with  
Mean FxS|| (SD) 
 
Delusions  29 (12.8) 
8.45 (2.87) 
Hallucinations  29 (12.8) 
6.86 (3.01) 
Agitation/Aggression  95 (41.9) 
7.27 (2.80) 
Depression  42 (18.5) 
7.29 (3.08) 
Anxiety  33 (14.5) 
8.18 (3.02) 
Euphoria  23 (10.1) 
8.04 (3.14) 
Apathy  93 (41.0) 
8.52 (3.28) 
Disinhibition  69 (30.4) 
8.07 (3.00) 
Irritability  84 (37.0) 
7.63 (2.63) 
Aberrant motor behavior  89 (39.2) 
8.47 (3.30) 
Nighttime behavior disturbances  37 (16.3) 
7.57 (2.97) 
Eating disturbances  43 (18.9) 
7.56 (2.86) 
PDU** n (%)  
Antipsychotics  71 (31.3) 
Anxiolytics  60 (26.4) 
Hypnotics  34 (15.0) 
Antidepressants  80 (35.2) 
Anti-epileptics  22 (9.7) 
Anti-dementia drugs  12 (5.3) 
Any psychotropic medication  152 (67.0) 
* Only the scores for residents included at T0 and residents included at T1 or T2 which not yet had been exposed 
to the intervention are shown. 
† CMAI = Cohen-Mansfield Agitation Inventory 
‡ SD = Standard Deviation  




§ NPI-NH = Neuropsychiatric Inventory-nursing home version 
|| Mean F x S = mean frequency x severity scores of clinical relevant NPI-NH scores  
**PDU = psychotropic drug use  
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Table 4. Effects of the intervention on NPS and PDU  
 
 Estimate P 95% CI 
   Lower bound Upper bound 
CMAI factor scores*     
 Physically non-
aggressive behaviors 
-.137 .825 -1.358 1.074 
Physically 
aggressive behaviors 
.495 .303 -.448 1.438 
Verbally agitated 
behaviors 
-.176 .697 -1.065 .713 
 
Clinical relevant  
NPI-NH† 
    
Delusions -.048 .136 -.111 .015 
Hallucinations .044 .135 -.014 .101 
Agitation/aggression -.001 .975 -.090 .087 
Depression .022 .560 -.052 .096 
Anxiety .034 .318 -.033 .102 
Euphoria .031 .338 -.033 .095 
Apathy .051 .320 -.051 .154 
Disinhibition .077 .092 -.013 .167 
Irritability- .000 .999 -.087 .087 
Aberrant motor 
behavior 
.049 .284 -.041 .139 
Nighttime behavior 
disturbances 
.050 .180 -.023 .122 
Eating disturbances .044 .253 -.031 .118 
 
PDU‡ 
    
Antipsychotics -.002 .956 -.064 .060 
Anxiolytics -.033 .301 -.095 .029 
Hypnotics -.021 .459 -.078 .035 
Antidepressants -.057 .066 -.117 .004 
Anti-epileptics .029 .126 -.008 .067 
Anti-dementia drugs -.005 .781 -.045 .044 
Any psychotropic 
medication 
-.023 .505 -.090 .044 
Estimate (i.e. regression coefficient) from multilevel model analyses with random effect for SCU and a random 
effect for resident, nested within SCU. P-value and 95%-CI were based on Wald-test and t-distribution with 
Satterthwaite approximation for the degrees of freedom. 
* CMAI = Cohen-Mansfield Agitation Inventory 
† NPI-NH = Neuropsychiatric Inventory-nursing home version 
 ‡ PDU = psychotropic drug use 
 
 
